HLA-A and non-small cell lung carcinoma: Based on these results, a multicentre, placebo-controlled, double blind, randomised phase 2b trial of Vx-001 was conducted in HLA-A*201-positive patients with metastatic and TERT-expressing NSCLC, who did not progress after 1st line platinum-based chemotherapy; the final results of the trial are presented in the current report.